Steroid "rescue dose" good for early births

9 February 2009

US researchers presented findings that show that premature babies, born before 34 weeks, have a 31% reduction in serious complications when  given a "rescue course" of antenatal corticosteroids, at the Society for  Maternal-Fetal Medicine's annual meeting .

Years ago doctors gave multiple courses of antenatal steroids to mothers  who were at risk for delivering prematurely. However, certain studies  found that there were possible adverse affects to multiple ACS courses  because babies were found to have slightly smaller head circumferences  and lower birth weights. As a result the National Institutes of Health  recommended further study.

Results of the study showed a significant reduction in composite  neonatal morbidity for babies born prior to 34 weeks in the "rescue  steroid" group versus placebo (43.9% vs 63.6%), as well as a significant  decrease in respiratory distress syndrome, ventilator support, and  surfactant use. When all neonates were included in the analysis  (regardless of the gestational age at delivery), a significant reduction  in composite morbidity in the "rescue steroid" group was still  demonstrated (32.1% vs 42.6%).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight